Delving into the Latest Updates on Novartis Pharmaceuticals UK Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Nervous System Diseases

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Infectious Diseases	1
Immune System Diseases	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

COX x COX-1 x COX-2	1
Bcr-Abl x STAMP	1
SQLE(Squalene monooxygenase)	1

A Phase I, open-label, two-part, fixed sequence, three period crossover study to investigate the drug-drug interaction potential of INE963 and KAE609 (Part A) administered together, and a two period crossover study to investigate the effect of food on pharmacokinetics and safety of INE963 (Part B), in healthy participants.

Start Date06 Oct 2023

Sponsor / Collaborator

Novartis Pharmaceuticals UK Ltd.

NCT04646109

/ CompletedPhase 3IIT

The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management

In this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe COVID-19 pneumonia that have no mutations which alter ivermectin metabolism and cause side effects.

Start Date11 May 2020

Sponsor / Collaborator

NeuTec Pharma Ltd.

100 Clinical Results associated with Novartis Pharmaceuticals UK Ltd.

Login to view more data

0 Patents (Medical) associated with Novartis Pharmaceuticals UK Ltd.

Login to view more data

164

Literatures (Medical) associated with Novartis Pharmaceuticals UK Ltd.

06 Jan 2025·International Journal of MS Care

PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Article

Author: Andiappan, Manoharan ; Coutts, Mhairi ; Evangelou, Nikos ; Rhys, Katherine ; Sawtell, Teresa ; Mattoscio, Miriam

ABSTRACTBACKGROUND:The PANORAMA survey aimed to assess current treatment practice for individuals with new diagnoses of relapsing-remitting multiple sclerosis (RRMS) in the United Kingdom and to explore variations in treatment approaches with an emphasis on escalation vs early high-efficacy treatment (HET) and treatment goals.METHODS:Health care professionals (HCPs) from the UK treating patients with RRMS took part in interviews facilitated by a structured questionnaire. Data were analyzed descriptively using quantitative or qualitative methods, as appropriate.RESULTS:Thirty-eight HCPs from 38 UK centers took part in the survey, including 20 MS consultants and 13 MS specialist nurses. Seventy-four percent (n = 28 of 38) of HCPs strongly agreed and 24% (9 of 38) agreed that early treatment is essential for better outcomes. HCPs reported that they currently treat a mean (SD) of 58.3% (20.8%) and 42.1% (21.8%) of patients with new diagnoses of RRMS with early HET or escalation approaches, respectively. Thirty-four percent (13 of 38) of HCPs reported a discrepancy between current treatment approach and the approach they would like to take, which would be 66.2% favoring early HET and 33.8% favoring escalation approaches. The factors influencing the choice of treatment approach were overall patient health profile (45%, 17 of 38) and patient choice (39%, 15 of 38). The most important treatment goals were to reduce relapses (63%, 24 of 38), delay disability progression (58%, 22 of 38), and maintain quality of life (50%, 19 of 38).CONCLUSIONS:The survey highlights variation among HCPs in the UK in current vs ideal use of escalation or early HET approaches and factors influencing choice of treatment approach.

01 Dec 2024·Environmental Monitoring and Assessment

Synthesis of calcium phosphate nanomaterial from quail eggshell for cadmium removal from wastewater and its genotoxic/cytotoxic properties

Article

Author: Turan, Funda ; Zaman, Buse Tuğba ; Çetin, Gülten ; Bakırdere, Bengisu Ece ; Bozyiğit, Gamze Dalgıç ; Nejati, Omid ; Ergenler, Ayşegül ; Bakırdere, Sezgin ; Demir, Cansu ; Öztürk, Ayça Bal ; Öner, Miray

In recent years, pollutants released into the environment from various sources threaten environmental health. Rapid industrialization and the constantly increasing needs of people facilitate the release of more hazardous wastes into the ecosystem. The presence of pollutants in water resources causes a wide range of adverse effects. In this study, calcium phosphate nanomaterial (Ca₃(PO₄)₂ NM) was synthesized from biological waste eggshells for the cadmium removal in synthetic domestic wastewater, and a treatment method was developed using these NMs. The Ca₃(PO₄)₂ NMs were produced by using a biowaste which provides the synthesis procedure greener approach. The biogenic NMs were used to remove toxic cadmium ions from wastewater samples. Cytotoxicity and genotoxicity studies of the synthesized NMs were also carried out, and their possible effects on the health of living organisms and the ecology were examined. In the developed method, the parameters affecting the removal of cadmium from wastewater samples were optimized and the removal efficiency was calculated by determining cadmium in a flame atomic absorption spectrophotometer system (FAAS). Synthetic domestic wastewater samples were utilized for evaluating the applicability of the developed treatment strategy. In addition, the adsorption capacity of the material for Cd²⁺ ion was calculated and the values obtained were modeled by using Langmuir adsorption isotherm (LAI). The calculated LAI parameters were within the appropriate limits, which proved that the developed NM can be used as an effective material for cadmium removal. Moreover, a new, rapid, and feasible synthesis strategy for the synthesis of Ca₃(PO₄)₂ NM was presented in the literature.

01 Dec 2024·Environmental Monitoring and Assessment

Removal of cadmium ions from synthetic wastewater samples by copper ferrite magnetic nanoparticle–assisted batch-type adsorption-based removal strategy

Article

Author: Bakırdere, Emine Gülhan ; Bozyiğit, Gamze Dalgıç ; Akbıyık, Hilal ; Zaman, Buse Tuğba ; Bakırdere, Sezgin ; Girgin, Ayça

Industrial activities can release a variety of harmful substances, including organic and inorganic components, into the environment. Inadequate treatment and discharge of these pollutants into aquatic environments might have adverse effects. Cadmium (Cd) is a toxic element found in various environmental sources, both anthropogenic and geogenic, which can contaminate soils and groundwater crucial for providing healthy food and safe drinking water. This study aimed to develop a novel strategy by the help of nano-sized adsorbents to remove cadmium ions from wastewater through batch-type adsorption processes. CuFe₂O₄ nanoparticles having high magnetic properties were synthesized using a co-precipitation process for the efficient removal of analyte. Characterization of the nanomaterial was performed using field emission scanning electron microscopy (FE-SEM), X-ray diffraction (XRD), and Brunauer-Emmett-Teller (BET) analysis. Method effective parameters were systematically optimized through univariate experiments to find proper conditions for the improvement of interaction between the adsorbent and cadmium ions. Removal efficiency (%RE) of Cd was assessed by using synthetic wastewater samples, and the accuracy/practicability of the recommended method proved highly efficient within the linear range of flame atomic absorption spectrophotometry (FAAS). In addition, the Langmuir isotherm model was applied to the experimental data, and the effective adsorption of cadmium from synthetic wastewater by the magnetic CuFe₂O₄ nanoparticles was proved.

100 Deals associated with Novartis Pharmaceuticals UK Ltd.

Login to view more data

100 Translational Medicine associated with Novartis Pharmaceuticals UK Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

3

4

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Asciminib Hydrochloride ( Bcr-Abl x STAMP )	Philadelphia chromosome positive chronic myelogenous leukemia More	Approved
Terbinafine Hydrochloride ( SQLE )	Onychomycosis More	Approved
Dexketoprofen Trometamol/Acetaminophen ( COX x COX-1 x COX-2 )	Pain More	Approved
Antazoline phosphate/naphazoline ( H1 receptor x α-adrenergic receptor )	Eye Infections More	Withdrawn
Efungumab ( HSP90 )	Candidiasis More	Discontinued